Media Kit

dedicated to driving psychedelic research, education
and innovation forward.

PsyTech is building a psychedelic health and wellness ecosystem, designed to elevate psychedelic medicine, foster normalization and accelerate innovation. PsyTech Summits bring together an engaged, passionate, and focused community of psychedelic industry players, researchers, and consumers.

Executive Team

HAYIM RACLAW

MANAGING DIRECTOR

Hayim is an adventurous business leader driven by the double bottom line of doing well financially and doing good in the world. He is experienced in international business development and financing and has spent his career building global healthcare companies for over 20 years. Recently, Hayim led iCAN’s Incubator, and took the helm at PsyTech in February 2020.

MARK GOLDHAR

DIRECTOR OF FINANCE

In his 15 years’ experience as a CPA, Mark has owned his own business, providing tax, consulting and CFO services to select clients. He served as a founding shareholder and CFO for two pharmaceutical cannabis companies, both of which resulted in exits as sales to public companies. Being a business leader in the cannabis space, Mark is well positioned to support PsyTech.

CAREY FRIED

MARKETING DIRECTOR

Carey is an experienced, creative and hard-working marketing executive with 15+ years of strategic, hands-on marketing experience. She knows that no job is too big or too small for a marketing exec and prides herself on building capable, inspired teams that deliver results aligned with business goals. She is a passionate about building solid businesses around great ideas.

Ronnie Eshel

YARON ESHEL

DIRECTOR OF LIFE SCIENCES

Yaron is a product development specialist and has been involved in several "First-in-Human" clinical trials, taking multiple companies through FDA and European regulatory approval. Having served as the Director of Life Sciences at iCAN, Yaron has the experience and knowledge necessary to guide our clinical and regulatory efforts forward.

Videos

Quote from Hayim Raclaw, Managing Director

"In the near future, psychedelic medicine will evolve to a point where people will be given the space to cure themselves of depression and to think in different, healthier ways. These elements, personalized medicine, different uses for different indications, psychiatric therapy and trip guidance are all going to improve - rapidly. Ultimately, those factors will absolutely reduce the use of selective serotonin reuptake inhibitors (SSRIs) and other antidepressants. And big pharma is going to be made to understand that there's a place for psychedelics and that people are going to demand access to those therapies. The success rates are so compelling that the drug companies will not be able to suppress this movement. I don't think that they will. I think we'll see the drug companies come in, in relatively short order."

KEREN TZARFATY, Ph.D.

CO-FOUNDER, THE HAKOMI INSTITUTE

CHRISTIAN ANGERMAYER

FOUNDER ATAI LIFE SCIENCES

JR RAHN

FOUNDER & CO-CEO MINDMED

RICK DOBLIN, PH.D.

EXECUTIVE DIRECTOR MULTIDISCIPLINARY ASSOCIATION FOR PSYCHEDELIC STUDIES (MAPS)

PsyTech Sponsors